Primary Sjögren's Syndrome Clinical Trial
Official title:
Assessment of Systemic Complications (Signs) and Evolution From Patients With Sjögren's Syndrome (ASSESS)
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health. Fifteen centers for autoimmune diseases consecutively included consecutive patients with Primary Sjögren's Syndrome "pSS" fulfilling American-European Consensus Criteria (AECG) between 2006 and 2009. The study was approved by the Ethics Committee of Bichat Hospital in 2006. All patients gave their informed written consent. This study was followed for 5 years with the grant of the French Ministry of Health and this study will be extended for 20 years by French Society of Rheumatology (SFR). On an annual basis for a duration of 20 years, a thorough standardized paper case report form (CRF) was filled prospectively by clinicians.
Primary Sjögren's syndrome (pSS) affects 0,1% of the population. This systemic autoimmune
disease is characterized by disabling dryness, fatigue and pain, and systemic complications
in 30% of patients. No treatment has proven effective in this disease. The previous or
present systemic complications included skin, articular, lung, kidney, peripheral and central
nervous system, muscular involvement and vasculitis, as well as lymphoma occurrence were
recorded. For previous lymphoma, the diagnosis and the histological subtypes were confirmed
by reanalysis of the medical and histological records. The objective of this cohort was to
assess systemic complications (signs) and evolution of patients with pSS and to determine the
evolution and factors predictors of lymphoma of systemic complications and lymphoma in pSS
during a 20-years prospective follow-up. This cohort was successful in rheumatology field,
395 patients was recruited for 2 years in 15 French centers (10 rheumatology and internal
medicine 5) and followed for 5 years until July 2014.
The primary objective of this cohort is to assess the evolution of Primitive Sjogren Syndrome
patients and to determine predictors factors of lymphoma and systemic complications during a
20-years prospective follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01989819 -
Primary Sjögren Syndrome
|
||
| Completed |
NCT02291029 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT02610543 -
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT04975087 -
The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory
|
||
| Recruiting |
NCT06203457 -
Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT04078386 -
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT05087589 -
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04212572 -
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
|
||
| Completed |
NCT02149420 -
PD of VAY736 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04858464 -
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
|
||
| Recruiting |
NCT03003572 -
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
|
||
| Completed |
NCT00632866 -
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
|
Phase 3 | |
| Completed |
NCT02334306 -
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02775916 -
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT02464319 -
A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
|
Phase 2 | |
| Terminated |
NCT01552681 -
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
|
Phase 2 | |
| Completed |
NCT04186871 -
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
| Completed |
NCT00426543 -
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
| Recruiting |
NCT04981145 -
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
|
Phase 4 | |
| Completed |
NCT03627065 -
A Study of INCB050465 in Primary Sjögren's Syndrome
|
Phase 2 |